A study by Sodhi and colleagues has shown that HMOs 2′-fucosyllactose (2′-FL) and 6′- sialyllactose (6′- SL) can reduce NEC severity through TLR4 inhibition (51). The gene discussed is TLR4; the disease is necrotizing enterocolitis.